# EDGAR Filing Document

**Accession Number:** 0000875045
**File Stem:** 0000875045-25-000023
**Filing Date:** 2025-6
**Character Count:** 6760
**Document Hash:** 10af292151d7ecf197b8d8e8c66899e5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000875045-25-000023.hdr.sgml**: 20250623

**ACCESSION NUMBER**: 0000875045-25-000023

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250617

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250623

**DATE AS OF CHANGE**: 20250623

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIOGEN INC.
- **CENTRAL INDEX KEY:** 0000875045
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 330112644
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-19311
- **FILM NUMBER:** 251065181

**BUSINESS ADDRESS:**
- **STREET 1:** 225 BINNEY STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 7814642000

**MAIL ADDRESS:**
- **STREET 1:** 225 BINNEY STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BIOGEN IDEC INC.
- **DATE OF NAME CHANGE:** 20070427

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BIOGEN IDEC INC
- **DATE OF NAME CHANGE:** 20031112

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IDEC PHARMACEUTICALS CORP / DE
- **DATE OF NAME CHANGE:** 19970530

?xml version='1.0' encoding='ASCII'? biib-20250617

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 17, 2025**

![New Biogen Logo.jpg](biib-20250617_g1.jpg)

**Biogen Inc.** 

*(Exact name of registrant as specified in its charter)* 

---

| | | |
|:---|:---|:---|
| **Delaware** | **0-19311** | **33-0112644** |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

---

**225 Binney Street, Cambridge, Massachusetts** 02142

(Address of principal executive offices; Zip Code)

&nbsp;&nbsp;&nbsp;&nbsp;

Registrant's telephone number, including area code: **(617) 679-2000** 

**Not Applicable**

(Former name or former address, if changed since last report.)

&nbsp;&nbsp;&nbsp;&nbsp;

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| **Common Stock, $0.0005 par value** | **BIIB** | **The Nasdaq Global Select Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

☐ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.07 &nbsp;&nbsp;&nbsp;&nbsp;Submission of Matters to a Vote of Security Holders.** 

On June 17, 2025, Biogen Inc. (the "Company") held its 2025 Annual Meeting of Stockholders (the "Annual Meeting"). The final voting results for the Annual Meeting are as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.Stockholders elected eleven nominees to the Board of Directors to serve for a one-year term extending until the 2026 annual meeting of stockholders and their successors are duly elected and qualified, with the votes cast as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Nominee** | **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| Caroline D. Dorsa | 90200723 | 25487099 | 321364 | 10206851 |
| Maria C. Freire | 96061538 | 19660536 | 287112 | 10206851 |
| William A. Hawkins | 96010449 | 19771738 | 226999 | 10206851 |
| Susan K. Langer | 96160359 | 19623542 | 225285 | 10206851 |
| Jesus B. Mantas | 93427720 | 22348175 | 233291 | 10206851 |
| Lloyd Minor | 114975935 | 692399 | 340852 | 10206851 |
| Menelas Pangalos | 114986403 | 695239 | 327544 | 10206851 |
| Monish Patolawala | 115162666 | 520650 | 325870 | 10206851 |
| Eric K. Rowinsky | 91034039 | 24745219 | 229928 | 10206851 |
| Stephen A. Sherwin | 95785706 | 19996175 | 227305 | 10206851 |
| Christopher A. Viehbacher | 114893329 | 883866 | 231991 | 10206851 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, with the votes cast as follows:

---

| | | | |
|:---|:---|:---|:---|
| **<u>Votes For</u>** | **<u>Votes Against</u>** | **<u>Abstentions</u>** | **<u>Broker Non-Votes</u>** |
| 120,065,433 | 5,916,416 | 234,188 |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Stockholders approved the advisory vote on executive compensation, with the votes cast as follows:

---

| | | | |
|:---|:---|:---|:---|
| **<u>Votes For</u>** | **<u>Votes Against</u>** | **<u>Abstentions</u>** | **<u>Broker Non-Votes</u>** |
| 78,531,756 | 37,113,368 | 364,062 | 10,206,851 |

---

**Item 9.01** &nbsp;&nbsp;&nbsp;&nbsp;**Financial Statements and Exhibits.**

**(d)&nbsp;&nbsp;&nbsp;&nbsp;Exhibits**

The exhibits listed below are furnished as part of this Current Report on Form 8-K.

---

| | |
|:---|:---|
| **<u>Exhibit No.</u>** | **<u>Description</u>** |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Biogen Inc.**

By: <u>/s/ Wendell Taylor&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;</u>

Wendell Taylor

Secretary

Date: June 23, 2025